The Clinical Validation of Modulated Electro-Hyperthermia (mEHT)

Abstract

The mEHT method uses tissues’ thermal and bioelectromagnetic heterogeneity for the selective mechanisms. The success of the therapy for advanced, relapsed, and metastatic aggressive tumors can only be demonstrated by measuring survival time and quality of life (QoL). The complication is that mEHT-treated patients cannot be curatively treated any longer with “gold standards”, where the permanent progression of the disease, the refractory, relapsing situation, the organ failure, the worsening of blood counts, etc., block them. Collecting a cohort of these patients is frequently impossible. Only an intent-to-treat (ITT) patient group was available. Due to the above limitations, many studies have single-arm data collection. The Phase III trial of advanced cervix tumors subgrouping of HIV-negative and -positive patients showed the stable efficacy of mEHT in all patients’ subgroups. The single-arm represents lower-level evidence, which can be improved by comparing the survival data of various studies from different institutes. The Kaplan–Meier probability comparison had no significant differences, so pooled data were compared to other methods. Following this approach, we demonstrate the feasibility and superiority of mEHT in the cases of glioblastoma multiform, pancreas carcinomas, lung tumors, and colorectal tumors.

Modulated Electro-Hyperthermia Accelerates Tumor Delivery and Improves Anticancer Activity of Doxorubicin Encapsulated in Lyso-Thermosensitive Liposomes in 4T1-Tumor-Bearing Mice

“…The tumor-specific damage of mEHT is based on the difference in the bioelectrical properties between the tumor and healthy tissues [ 28 ]. This bioelectrical difference results from the higher aerobic glycolysis of cancer cells that causes higher ion and lactate levels and thereby elevates the electric conductivity of the tumor [ 29 , 30 ]. These factors result in the selective absorption of the energy of an electromagnetic field by the tumor tissue [ 28 ].…”

Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model

“…Modulated electro-hyperthermia (mEHT) is a noninvasive adjuvant cancer treatment approved for clinical use in different cancer types. − mEHT uses an amplitude-modulated, 13.56 MHz radiofrequency electromagnetic field by capacitive coupling between two electrodes surrounding the cancer. , Due to the difference in bioelectrical properties between cancerous and healthy tissues, , the electromagnetic field energy is absorbed mainly by cancer tissues, resulting in cancer-specific tissue damage. , At the cellular level, mEHT generates heat, leading to cellular stress and upregulation of HSPs . We previously demonstrated enhanced anticancer effects of mEHT by inhibiting HSP70 in vitro and heat shock factor 1 (HSF1) in vivo, utilizing the small molecule inhibitors of the heat shock response central regulator (i.e., HSF1): quercetin and KRIBB11, and by knocking down HSF1 production of the tumor cells with a CRISPR/Cas9 construct .…”